NVH Medicinal is a private company developing genetically engineered protein-based therapies for hemostasis and regenerative medicine.
NVH-020 is a first-in class recombinant collagen-like protein belonging to a new class of engineered protein now referred as recombinamer with potent platelet activity.
A unique and differentiated commercial offer to speed up the development of recombinant protein-based products
|PROTEIN AND ANTIBODY ENGINEERING||BIOPRODUCTION||BIOLOGICAL ACTIVITY VALIDATION||PRECLINICAL EFFICACY||CLINICAL TRIALS|
|Customized engineered-derivative or chimeric recombinant proteins. Conception of new engineered-protein using rational design (synthetic biology)||• DNA vector construction • Protein production (mg-g) from bacteria or mammalian cells (HEK, CHO) • Stable cell line generation • Protein purification • Process optimization||• In vitro ligand binding activity • In vitro assessment of bioactivity • Custom-tailored cell-based models • In vitro immuno-genicity risk assessment • In vivo pharmaco-kinetics and biodistribution||• Proof of efficacy studies in a wide range of experimental models of human pathologies • In vitro cell-disease models • In vivo animal models • Evaluation of customized imaging companion diagnostics||• INCa accredited center of early phases clinical trials in oncology (Phase 1) • 20-25 % patients included in biomedical research studies|
For correspondance (headquarter)NVH Medicinal
To meet usCHU Hôpital d'enfants - bâtiment recherche